Home > Publications Database > Serum neurofilament light chain in behavioral variant frontotemporal dementia. > print

001     140376
005     20240826135844.0
024 7 _ |a 10.1212/WNL.0000000000006318
|2 doi
024 7 _ |a pmid:30209235
|2 pmid
024 7 _ |a 0028-3878
|2 ISSN
024 7 _ |a 1526-632X
|2 ISSN
024 7 _ |a altmetric:48498238
|2 altmetric
037 _ _ |a DZNE-2020-06698
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Steinacker, Petra
|b 0
245 _ _ |a Serum neurofilament light chain in behavioral variant frontotemporal dementia.
260 _ _ |a [S.l.]
|c 2018
|b Ovid
264 _ 1 |3 online
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2018-09-12
264 _ 1 |3 print
|2 Crossref
|b Ovid Technologies (Wolters Kluwer Health)
|c 2018-10-09
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1724673498_30327
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Objective: To determine the association of serum neurofilament light chain (NfL) with functional deterioration and brain atrophy during follow-up of patients with behavioral variant frontotemporal dementia (bvFTD).Methods: Blood NfL levels from 74 patients with bvFTD, 26 with Alzheimer disease (AD), 17 with mild cognitive impairment (MCI), and 15 healthy controls (Con) at baseline and follow-up were determined and analyzed for the diagnostic potential in relation to functional assessment (Clinical Dementia Rating Scale Sum of Boxes [CDR-SOB], frontotemporal lobar degeneration–related CDR-SOB, Mini-Mental State Examination [MMSE]) and brain volumetry.Results: At baseline, serum NfL level correlated with CSF NfL (bvFTD r = 0.706, p < 0.0001; AD/MCI r = 0.666, p = 0.0003). Highest serum levels were observed in bvFTD (p <0 0.0001 vs Con and MCI, p = 0.0078 vs AD, respectively). Discrimination of bvFTD from Con/MCI/AD was possible with 91%/74%/74% sensitivity and 79%/74%/58% specificity. At follow-up, serum NfL increased in bvFTD and AD (p = 0.0039 and p = 0.0006, respectively). At baseline and follow-up, NfL correlated with functional scores of patients with bvFTD (e.g., CDR-SOB [baseline] r = 0.4157, p = 0.0006; [follow-up] r = 0.5629, p < 0.0001) and with atrophy in the gray and white matter of many brain regions including frontal and subcortical areas (e.g., frontal lobe: r = −0.5857, p < 0.0001; 95% confidence interval −0.7415 to −0.3701). For patients with AD/MCI, NfL correlated with the functional performance as well (e.g., CDR-SOB [baseline] r = 0.6624, p < 0.0001; [follow-up] r = 0.5659, p = 0.0003) but not with regional brain volumes.Conclusions: As serum NfL correlates with functional impairment and brain atrophy in bvFTD at different disease stages, we propose it as marker of disease severity, paving the way for its future use as outcome measure for clinical trials.Classification of evidence: This study provides Class III evidence that for patients with cognitive problems, serum NfL concentration discriminates bvFTD from other forms of dementia.
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 0
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: blood
|2 MeSH
650 _ 2 |a Alzheimer Disease: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Alzheimer Disease: diagnostic imaging
|2 MeSH
650 _ 2 |a Alzheimer Disease: genetics
|2 MeSH
650 _ 2 |a Atrophy
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Biomarkers: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: blood
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: cerebrospinal fluid
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: diagnostic imaging
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: genetics
|2 MeSH
650 _ 2 |a Diagnosis, Differential
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Follow-Up Studies
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: blood
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: diagnostic imaging
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: pathology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Mutation
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Organ Size
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
700 1 _ |a Anderl-Straub, Sarah
|b 1
700 1 _ |a Diehl-Schmid, Janine
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Semler, Elisa
|b 3
700 1 _ |a Uttner, Ingo
|b 4
700 1 _ |a von Arnim, Christine A F
|b 5
700 1 _ |a Barthel, Henryk
|b 6
700 1 _ |a Danek, Adrian
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Fassbender, Klaus
|b 8
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Foerstl, Hans
|b 10
700 1 _ |a Grimmer, Timo
|b 11
700 1 _ |a Huppertz, Hans-Jürgen
|b 12
700 1 _ |a Jahn, Holger
|b 13
700 1 _ |a Kassubek, Jan
|b 14
700 1 _ |a Kornhuber, Johannes
|b 15
700 1 _ |a Landwehrmeyer, Bernhard
|b 16
700 1 _ |a Lauer, Martin
|b 17
700 1 _ |a Maler, Juan Manuel
|b 18
700 1 _ |a Mayer, Benjamin
|b 19
700 1 _ |a Oeckl, Patrick
|b 20
700 1 _ |a Prudlo, Johannes
|0 P:(DE-2719)2380559
|b 21
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 22
|u dzne
700 1 _ |a Volk, Alexander E
|b 23
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 24
700 1 _ |a Schroeter, Matthias L
|b 25
700 1 _ |a Ludolph, Albert C
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Otto, Markus
|0 P:(DE-HGF)0
|b 27
|e Corresponding author
700 1 _ |a group, FTLDc study
|b 28
700 1 _ |a Albrecht, Franziska
|b 29
700 1 _ |a Bisenius, Sandrine
|b 30
700 1 _ |a Feneberg, Emily
|b 31
700 1 _ |a Haefner, Sibylle
|b 32
700 1 _ |a Kasper, Elisabeth
|0 P:(DE-HGF)0
|b 33
700 1 _ |a Kurzwelly, Delia
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Lampe, Leonie
|b 35
700 1 _ |a Levin, Johannes
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Lornsen, Finn
|b 37
700 1 _ |a Luley, Maxine
|b 38
700 1 _ |a Oberstein, Timo
|b 39
700 1 _ |a Pellkofer, Hannah
|b 40
700 1 _ |a Prix, Catharina
|b 41
700 1 _ |a Richter-Schmidinger, Tanja
|b 42
700 1 _ |a Roth, Nina
|b 43
700 1 _ |a Sabri, Osama
|b 44
700 1 _ |a Schachner, Lisa
|b 45
700 1 _ |a Schomburg, Robert
|b 46
700 1 _ |a Schönecker, Sonja
|b 47
700 1 _ |a Schuemberg, Katharina
|b 48
700 1 _ |a Spottke, Annika
|0 P:(DE-HGF)0
|b 49
700 1 _ |a Teipel, Stefan
|0 P:(DE-HGF)0
|b 50
700 1 _ |a Wilken, Petra
|0 P:(DE-HGF)0
|b 51
700 1 _ |a Zech, Heike
|b 52
773 1 8 |a 10.1212/wnl.0000000000006318
|b : Ovid Technologies (Wolters Kluwer Health), 2018-09-12
|n 15
|p e1390-e1401
|3 journal-article
|2 Crossref
|t Neurology
|v 91
|y 2018
|x 0028-3878
773 _ _ |a 10.1212/WNL.0000000000006318
|g Vol. 91, no. 15, p. e1390 - e1401
|0 PERI:(DE-600)1491874-2
|n 15
|q 91:15|p e1390-e1401
|t Neurology
|v 91
|y 2018
|x 0028-3878
909 C O |p VDB
|o oai:pub.dzne.de:140376
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2380559
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 22
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2811317
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 1
914 1 _ |y 2018
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2022-11-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-12
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEUROLOGY : 2021
|d 2022-11-12
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 0
920 1 _ |0 I:(DE-2719)1410006
|k AG Wiltfang
|l Molecular biomarkers for predictive diagnostics of neurodegenerative diseases
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1410006
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21